Understanding the Role of C-peptide Levels in Monitoring the Honeymoon Period

Understanding the Honeymoon Period and the Role of C‑peptide

The honeymoon period—clinically termed the partial remission phase—represents a temporary but clinically important window that occurs shortly after the diagnosis of type 1 diabetes. During this phase, the surviving beta cells in the pancreas partially recover their ability to secrete insulin, often enabling patients to maintain near‑normal blood glucose levels with significantly lower doses of exogenous insulin. This “honeymoon” can last for weeks, months, or even up to a year or more in some individuals, particularly those diagnosed later in childhood or as adults.

One of the most valuable tools for tracking this phase is the measurement of C‑peptide, a peptide fragment released alongside insulin in equimolar amounts. Understanding C‑peptide levels during the honeymoon period helps clinicians evaluate residual beta‑cell function, adjust therapy appropriately, predict disease progression, and identify candidates for emerging disease‑modifying therapies. This article provides a comprehensive, clinically focused examination of what C‑peptide is, why it matters during the honeymoon phase, how to interpret high and low levels, and how systematic monitoring can improve diabetes management for patients and families.

Why the Honeymoon Period Matters in Clinical Practice

The honeymoon period is clinically significant because it represents the best opportunity for preserving whatever beta‑cell function remains after the autoimmune attack. Preserved endogenous insulin secretion is associated with better glycemic control, fewer hypoglycemic events, lower glycemic variability, and a reduced risk of long‑term complications including nephropathy, retinopathy, and cardiovascular disease. Moreover, the duration and intensity of the honeymoon phase can influence the choice of insulin regimen and the potential for using newer therapies—such as teplizumab or other immunomodulators—that aim to protect remaining beta cells from further destruction.

From a patient perspective, the honeymoon period can be both a relief and a source of confusion. Families may question whether the diagnosis was incorrect, especially if insulin needs drop dramatically. Clear communication about the transient nature of this phase and the importance of continued monitoring is essential to prevent dangerous lapses in therapy when endogenous insulin production eventually declines.

What Is C‑peptide and How Is It Connected to Insulin?

C‑peptide (connecting peptide) is a short chain of 31 amino acids produced when proinsulin—the precursor molecule synthesized in pancreatic beta cells—is enzymatically cleaved to form equimolar amounts of insulin and C‑peptide. Because insulin and C‑peptide are released into the portal circulation in a 1:1 ratio, measuring C‑peptide provides a direct and reliable proxy for endogenous insulin secretion. Unlike insulin, which is rapidly cleared by the liver with a half‑life of only 3–5 minutes, C‑peptide is eliminated more slowly (half‑life of 30–35 minutes) and is more stable in both blood and urine samples, making it a practical and reproducible marker of beta‑cell function.

In healthy individuals, C‑peptide levels rise appropriately after meals and fall during fasting, reflecting normal glucose‑stimulated insulin secretion. In people with diabetes, any detectable C‑peptide indicates residual endogenous insulin production, even if the patient requires exogenous insulin to achieve glycemic targets. A measurable stimulated C‑peptide level—typically above 0.2 nmol/L—is a sign that some beta cells are still functioning, which carries important prognostic and therapeutic implications.

How Is C‑peptide Measured in Clinical Practice?

C‑peptide can be measured from a blood sample (plasma or serum) or from a 24‑hour urine collection. The most common clinical test is a fasting C‑peptide level, but a stimulated C‑peptide measurement—obtained after a mixed meal, oral glucose load, or glucagon challenge—provides a more dynamic and informative assessment of beta‑cell reserve. Stimulated testing is generally preferred for evaluating residual function because it challenges the beta cells to respond and reveals their true secretory capacity.

Laboratories typically report results in nanomoles per liter (nmol/L) or nanograms per milliliter (ng/mL). Reference ranges vary by laboratory and assay, but generally a fasting C‑peptide above 0.5 nmol/L indicates some preserved insulin secretion, while a stimulated level above 0.6–0.7 nmol/L suggests meaningful residual function. It is critical to interpret C‑peptide values together with concurrent blood glucose levels. For example, a low C‑peptide in the presence of hyperglycemia confirms insulin deficiency, whereas a relatively high C‑peptide with low blood glucose may suggest exogenous insulin overdosing—sometimes called the Hagedorn phenomenon or factitious hypoglycemia.

The Significance of C‑peptide Levels During the Honeymoon Phase

During the honeymoon period, the beta cells that survived the initial autoimmune attack may undergo a period of functional recovery or “metabolic rest,” leading to improved insulin secretion. C‑peptide levels often rise or remain stable during this time, reflecting that recovery. Monitoring C‑peptide serially provides an objective, quantitative measure of how much endogenous insulin the patient is producing and helps clinicians make informed decisions about when to adjust therapy.

The trajectory of C‑peptide over time is more clinically informative than any single reading. A plateau or slow decline may allow continued use of a simpler insulin regimen, while a rapid drop signals that the honeymoon is ending and more intensive therapy is needed. Research has shown that preserved C‑peptide levels at 1 year post‑diagnosis are associated with lower HbA1c and fewer severe hypoglycemic events over long‑term follow‑up.

High C‑peptide Levels: Implications and Management

A high or rising C‑peptide level during the honeymoon period is a favorable sign. It suggests that beta cells are still capable of mounting a meaningful insulin response, which may allow the patient to reduce or even temporarily discontinue exogenous insulin. However, high levels do not guarantee a prolonged remission; they merely indicate that at that point in time, insulin production is relatively preserved. In clinical practice, a stimulated C‑peptide above 0.6 nmol/L is often used as a threshold for considering a cautious reduction in insulin dose.

Key implications of high C‑peptide include:

Possibility of lower insulin doses – Patients may maintain target glucose levels with minimal basal insulin alone, or even without prandial coverage in some cases.
Lower risk of severe hypoglycemia – Endogenous insulin secretion provides a more physiologic response to meals, exercise, and stress, reducing dangerous glucose swings.
Better glycemic variability – Studies consistently show that preserved C‑peptide is associated with less day‑to‑day glucose fluctuation and lower HbA1c.
Extended honeymoon duration – Higher C‑peptide at diagnosis is a strong predictor of a longer remission phase.

Management during this phase should focus on maintaining excellent glycemic control to protect remaining beta cells from glucotoxicity. Intensive glucose monitoring—either through frequent self‑monitoring or continuous glucose monitoring (CGM)—is essential to detect when insulin needs begin to increase again. Some clinicians use C‑peptide levels to guide decisions about insulin pump settings or the use of hybrid closed‑loop systems, which may be particularly beneficial in preserving residual function.

Low C‑peptide Levels: Recognizing the End of Remission

A low or declining C‑peptide level indicates that beta‑cell function is waning, usually signaling that the honeymoon period is drawing to a close. Once C‑peptide falls below a certain threshold—generally a stimulated level of less than 0.2 nmol/L—the patient will require increasing amounts of exogenous insulin to maintain glycemic control. A low C‑peptide prompts the clinical team to increase basal insulin, intensify the overall regimen, and re‑educate the patient and family about the risks of diabetic ketoacidosis (DKA).

Implications of low C‑peptide include:

Need for higher insulin doses – Exogenous insulin must compensate for the deficit, often requiring a transition from simple basal therapy to full basal‑bolus regimens.
Higher risk of diabetic ketoacidosis – When endogenous insulin production is negligible, any illness, missed dose, or pump failure can rapidly lead to DKA.
Loss of endogenous regulation – Patients become more dependent on external insulin timing and dosing accuracy, requiring more frequent glucose monitoring and carbohydrate counting.
Potential for glycemic instability – Without endogenous insulin buffering, glucose levels may become more erratic, with wider swings between hyperglycemia and hypoglycemia.

When C‑peptide declines, clinicians should also consider checking autoantibodies and ketone levels more frequently, and ensure that patients have a clear sick‑day management plan that includes ketone testing and emergency contact protocols.

Monitoring C‑peptide for Better Diabetes Management

Regular monitoring of C‑peptide levels—typically every 3 to 6 months during the first year after diagnosis—can guide clinical decisions and help set realistic expectations for patients and families. The trajectory of C‑peptide is more informative than a single reading. A plateau or slow decline may allow continued use of a simpler regimen, while a rapid drop signals the need for more aggressive insulin therapy and enhanced education about DKA prevention.

Tailoring Treatment Plans Based on C‑peptide Status

Knowing a patient’s current C‑peptide level helps customize the insulin plan in a nuanced way:

High C‑peptide (stimulated > 0.6 nmol/L): Focus on basal insulin only, or consider a low‑carbohydrate diet to reduce postprandial excursions and preserve beta‑cell function. Some patients may tolerate temporary insulin cessation under close monitoring.
Moderate C‑peptide (0.2–0.6 nmol/L stimulated): Use a combination of basal and prandial insulin, but with lower doses than typical for established type 1 diabetes. Consider rapid‑acting analogs to match the patient’s residual secretion pattern.
Low or absent C‑peptide (< 0.2 nmol/L stimulated): Full basal‑bolus regimen or insulin pump therapy is indicated. Close monitoring for ketones during illness is essential, and patients should understand that the honeymoon is effectively over.

C‑peptide monitoring also informs decisions about emerging technologies. For instance, patients with preserved C‑peptide may benefit more from sensor‑augmented pump therapy or hybrid closed‑loop systems that can better accommodate residual insulin secretion.

Predicting Disease Progression and Long‑Term Outcomes

C‑peptide levels are the strongest single predictor of disease progression in new‑onset type 1 diabetes. Clinical trials investigating disease‑modifying therapies—such as anti‑CD3 antibodies (teplizumab), CTLA4‑Ig (abatacept), antigen‑based vaccines, and autologous stem cell therapy—routinely use stimulated C‑peptide as a primary endpoint. Preserving C‑peptide is associated with lower HbA1c, fewer severe hypoglycemic events, reduced risk of DKA, and a lower incidence of diabetic complications over the long term, including retinopathy and nephropathy.

Research published in Diabetes Care has shown that every 1 pmol/mL increase in stimulated C‑peptide at 1 year post‑diagnosis is associated with a 30–40% reduction in the risk of developing microvascular complications over the subsequent decade. These data underscore why C‑peptide preservation is a central goal of both clinical care and drug development.

Distinguishing Type 1 from Type 2 Diabetes in Ambiguous Cases

In adults with newly diagnosed diabetes, measuring C‑peptide helps differentiate between type 1 and type 2. A low C‑peptide with positive autoantibodies (GAD, IA‑2, ZnT8, or ICA) confirms type 1 diabetes. Occasionally, patients with latent autoimmune diabetes in adults (LADA) may show intermediate C‑peptide levels—often due to slower progression—requiring careful longitudinal follow‑up. The honeymoon period in LADA can be more prolonged and subtle than in classic type 1, sometimes persisting for months or even years. In such cases, serial C‑peptide measurements are invaluable for tracking when insulin therapy needs to be escalated.

Clinical Staging and the Honeymoon Period

The modern staging of type 1 diabetes includes a presymptomatic phase: stage 1 is characterized by autoimmunity with normoglycemia; stage 2 involves dysglycemia without symptoms; and stage 3 corresponds to clinical onset with hyperglycemia and symptoms. The honeymoon period corresponds to the early part of stage 3, when beta‑cell function is still relatively preserved after the initial metabolic crisis. C‑peptide levels are often measurable and even relatively high at diagnosis, then decline over subsequent months at a rate that varies widely among individuals.

Factors That Influence the Rate of C‑peptide Decline

Understanding the factors that affect C‑peptide decline can help clinicians counsel patients and anticipate the trajectory of their disease:

Age at diagnosis: Younger children—especially those under 5 years—tend to have a more rapid loss of beta‑cell function, with C‑peptide declining to undetectable levels within 1–2 years.
Metabolic control at onset: Initial glycemic control, particularly avoiding DKA, may slow the decline. Intensive glucose management during the first months has been associated with better preservation of C‑peptide.
Autoantibody profile: Patients with multiple positive autoantibodies often have a faster decline than those with only one or two.
Genetic factors: Certain HLA types (especially DR3/DR4) and non‑HLA variants influence the rate of beta‑cell destruction.
Residual beta‑cell mass: The number of functional beta cells remaining at diagnosis is a key determinant of how long the honeymoon period lasts.
Lifestyle interventions: Some evidence suggests that a very low‑carbohydrate diet or other dietary modifications may help preserve C‑peptide, though more research is needed.

Practical Guide to Using C‑peptide in the Clinic

When monitoring a patient during the honeymoon period, clinicians should follow a systematic approach to maximize the clinical utility of C‑peptide measurements:

Obtain a baseline stimulated C‑peptide within 2–4 weeks of diagnosis, once the initial metabolic decompensation has resolved. This provides a reference point for future comparisons.
Repeat a stimulated C‑peptide every 3–6 months during the first year, and then every 6–12 months until levels become very low (< 0.1 nmol/L) or undetectable.
Always correlate C‑peptide with concurrent glucose levels, insulin doses (total daily dose and type), and the frequency of hypoglycemic events. A single C‑peptide value without glucose context can be misleading.
Use declining C‑peptide as a trigger to intensify insulin therapy, re‑educate on glucose monitoring and ketone testing, and discuss the transition from honeymoon to established disease.
Consider discussing clinical trial opportunities if C‑peptide is preserved above 0.2 nmol/L, particularly for trials investigating beta‑cell preservation or immunomodulation.

Limitations of C‑peptide Monitoring

While C‑peptide is an invaluable biomarker, it has important limitations that clinicians must keep in mind:

Renal impairment: In patients with reduced glomerular filtration rate, C‑peptide clearance is diminished, leading to falsely elevated levels. This is particularly relevant in older adults or those with pre‑existing kidney disease.
Assay interferences: Some patients develop antibodies against proinsulin that can interfere with C‑peptide immunoassays, producing spurious results.
Metabolic suppression: Strict glycemic control can suppress endogenous insulin secretion through “metabolic recovery” or “beta‑cell rest,” meaning that a low C‑peptide during intensive therapy may not reflect true beta‑cell mass or potential.
Inability to measure beta‑cell mass: C‑peptide reflects insulin secretion, not the actual number of viable beta cells. A low level could mean reduced beta‑cell mass or simply suppressed function.
Lack of standardization: Different assays may yield slightly different results, so it is best to use the same laboratory and assay for serial measurements in the same patient.

Future Directions: C‑peptide as a Biomarker in Research and Emerging Therapies

C‑peptide is far more than just a clinical tool—it is a key outcome measure in studies of beta‑cell preservation and disease modification. The landmark TrialNet study showed that teplizumab, an anti‑CD3 monoclonal antibody, delayed progression from stage 2 to stage 3 diabetes by a median of 2 years, with preservation of stimulated C‑peptide as the primary evidence of efficacy. Similarly, trials of verapamil, alefacept, abatacept, and autologous stem cell transplantation have all used C‑peptide trajectories to gauge therapeutic success.

The National Institutes of Health and the Juvenile Diabetes Research Foundation continue to fund large‑scale studies that rely on C‑peptide as a surrogate endpoint. Newer technologies are also emerging. For example, continuous glucose monitoring data combined with C‑peptide measurements are being explored to provide real‑time insights into residual insulin secretion and its relationship with glycemic patterns. Some researchers are investigating whether mathematical modeling of C‑peptide kinetics can predict the timing of clinical events such as DKA or severe hypoglycemia.

Urine C‑peptide creatinine ratio (UCPCR) is a non‑invasive alternative that correlates well with stimulated plasma C‑peptide and may become more common in outpatient monitoring, especially for children or patients who prefer to avoid repeated blood draws. Studies have shown that UCPCR can effectively track beta‑cell function over time and predict the end of the honeymoon period with reasonable accuracy.

Patient and Family Education: Making C‑peptide Understandable

For patients and families, understanding that a higher C‑peptide level means their own pancreas is still contributing to insulin production can be empowering and motivating. Clinicians should explain C‑peptide in accessible terms: “Think of it as a measure of how hard your pancreas is still working. When it’s high, your body is making much of the insulin it needs. When it drops, we’ll need to increase your insulin injections to make up for the loss.”

This knowledge can help families accept the gradual increase in insulin needs without feeling that they are “failing” at diabetes management. It also provides a concrete biological marker to discuss during clinic visits, making the abstract concept of beta‑cell function more tangible. Support groups and diabetes education programs can incorporate C‑peptide monitoring as part of a broader understanding of the disease trajectory.

Conclusion

The honeymoon period offers a critical window of opportunity to preserve beta‑cell function, and C‑peptide stands out as the most direct, reliable, and clinically useful marker of that function. By monitoring C‑peptide levels systematically and interpreting them in the context of concurrent glucose levels and insulin doses, clinicians can tailor insulin regimens to each patient’s current needs, anticipate the end of remission, and identify candidates for emerging disease‑modifying therapies. For patients and their families, understanding that C‑peptide reflects their own residual insulin production can provide a sense of agency and encourage consistent glucose management during a challenging transitional period.

As research continues to advance—with new immunomodulatory agents, beta‑cell preservation strategies, and non‑invasive monitoring technologies on the horizon—C‑peptide will remain a cornerstone of both clinical care and drug development. Preserving even a modest amount of endogenous insulin secretion can translate into meaningful improvements in long‑term outcomes, including fewer complications, better quality of life, and reduced treatment burden. For clinicians caring for individuals with new‑onset type 1 diabetes, making C‑peptide monitoring a standard part of follow‑up is one of the most impactful practices they can adopt.

For further reading, see the Endotext chapter on C‑peptide measurement, the American Diabetes Association’s Standards of Care section on monitoring beta‑cell function, the comprehensive review on the honeymoon period in type 1 diabetes, and the TrialNet website for information on clinical trials targeting beta‑cell preservation.